Elizabeth Crowley - Celldex Therapeutics President
| CLDX Stock | USD 37.77 1.08 2.78% |
President
Ms. Elizabeth Crowley is Senior Vice President, Chief Product Development Officer of the Company. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporationrationration, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution since 2016.
| Age | 52 |
| Tenure | 8 years |
| Address | Perryville III Building, Hampton, NJ, United States, 08827 |
| Phone | 908 200 7500 |
| Web | https://www.celldex.com |
Celldex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.217) % which means that it has lost $0.217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3745) %, meaning that it created substantial loss on money invested by shareholders. Celldex Therapeutics' management efficiency ratios could be used to measure how well Celldex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.34 in 2024. At this time, Celldex Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 453.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 31 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Mark Schlossberg | Cytokinetics | 57 | |
| Stephen Betz | Crinetics Pharmaceuticals | 58 | |
| Ching Jaw | Cytokinetics | 61 | |
| Martin Daley | Dyne TherapeuticsInc | 60 | |
| Andrew Wolff | Cytokinetics | 61 | |
| Gina Ford | Crinetics Pharmaceuticals | N/A | |
| Yujiro Hata | Ideaya Biosciences | 50 | |
| Fady Malik | Cytokinetics | 53 | |
| Ajay Madan | Crinetics Pharmaceuticals | 49 | |
| Aaron Solomon | Cogent Biosciences | 32 | |
| Robert Wong | Cytokinetics | 56 | |
| Caryn McDowell | Cytokinetics | 46 | |
| Mario Alonso | Dyne TherapeuticsInc | 45 | |
| Sharon Barbari | Cytokinetics | 61 | |
| Catherine James | Dyne TherapeuticsInc | 50 | |
| Peter Roddy | Cytokinetics | 56 | |
| Dean Ellis | Dyne TherapeuticsInc | 46 | |
| Elisabeth Schnieders | Cytokinetics | 49 | |
| James Reilly | Cogent Biosciences | 42 | |
| Matthew Conlin | Cogent Biosciences | 33 | |
| YunFei Zhu | Crinetics Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 |
Celldex Therapeutics Leadership Team
Elected by the shareholders, the Celldex Therapeutics' board of directors comprises two types of representatives: Celldex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celldex. The board's role is to monitor Celldex Therapeutics' management team and ensure that shareholders' interests are well served. Celldex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celldex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Till, Senior Communications | ||
| Prof Schlessinger, CoFounder Board | ||
| Keith Brownlie, Director | ||
| Diane MD, Senior Officer | ||
| Sam Martin, CFO, Senior Vice President | ||
| Gerald McMahon, Director | ||
| Margo MD, Senior Affairs | ||
| Sarah Cavanaugh, Vice President Investor Relations & Corporate Communications | ||
| James Marino, Director | ||
| George Elston, Independent Director | ||
| Freddy Esq, Senior Counsel | ||
| Thomas Davis, Senior Vice President Chief Medical Officer | ||
| Richard Wright, Senior Vice President Chief Commercial Officer` | ||
| Anthony MBA, President, Founder | ||
| Theresa LaVallee, Senior Vice President - Regulatory and Precision Medicine | ||
| Ronald Pepin, Chief Bus. Officer and Sr. VP | ||
| Harry Penner, Independent Director | ||
| Karen Shoos, Independent Director | ||
| Richard Broek, Director | ||
| Anthony Marucci, President CEO, Director | ||
| Diane Young, Senior Vice President Chief Medical Officer | ||
| Avery Catlin, CFO, Principal Accounting Officer, Sr. VP, Treasurer and Secretary | ||
| Elizabeth Crowley, Senior Vice President Chief Product Development Officer | ||
| Larry Ellberger, Independent Chairman of the Board | ||
| Herbert Conrad, Independent Director | ||
| Margo HeathChiozzi, Senior Vice President - Regulatory Affairs | ||
| Tibor Keler, Founder, Chief Scientific Officer and Executive VP |
Celldex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celldex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.50) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 65.7 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 96.78 % | ||||
| Number Of Shares Shorted | 6.56 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 6.01 X |
Celldex Therapeutics Investors Sentiment
The influence of Celldex Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Celldex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Celldex Therapeutics' public news can be used to forecast risks associated with an investment in Celldex. The trend in average sentiment can be used to explain how an investor holding Celldex can time the market purely based on public headlines and social activities around Celldex Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Celldex Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Celldex Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Celldex Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Celldex Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Celldex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Celldex Therapeutics' short interest history, or implied volatility extrapolated from Celldex Therapeutics options trading.
Pair Trading with Celldex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celldex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celldex Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Celldex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celldex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celldex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celldex Therapeutics to buy it.
The correlation of Celldex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celldex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celldex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celldex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Revenue Per Share 0.142 | Quarterly Revenue Growth 1.561 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.